STAT Plus: Drug companies try to catch the rising wave of RNAi medicines
NIH
Within the last month, Eli Lilly, Alexion, and Janssen have all announced licensing and collaboration deals with companies developing RNAi treatments.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario